Download Files:
Izencitinib
$260 – $2,160
Products Details
Product Description
– Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis[1].
Web ID
– HY-109148
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H26N8
References
– [1]William J Sandborn, et al. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16;14(9):1202-1213.|[2]D. Beattie, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. Journal of Crohn’s and Colitis, Volume 10, Issue suppl_1, March 2016, Page S123.|[3]Kevin S Currie, et al. Small-molecule agents for the treatment of inflammatory bowel disease. Bioorg Med Chem Lett. 2019 Aug 15;29(16):2034-2041.
CAS Number
– 2051918-33-1
Molecular Weight
– 402.50
Compound Purity
– 98.0
SMILES
– CC1=CC(NC2=CC3=C(C=CC=N3)C(N[C@@H]4C[C@@H](CC5)N(CCC#N)[C@@H]5C4)=N2)=NN1
Clinical Information
– Phase 3
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– JAK
Pathway
– Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
